Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.
暂无分享,去创建一个
Karl J. Dykema | K. Dykema | J. MacKeigan | N. Monks | E. Eugster | David Cherba | C. Webb | B. Nickoloff | N. Duesbery | P. Davidson | M. Winn | Andrew S Borgman | D. Monsma | C. Peterson | D. Dylewski